Solventum (NYSE:SOLV) yesterday announced fourth-quarter results that came in ahead of the consensus forecast on Wall Street.
Thermo Fisher Scientific is expanding its life sciences portfolio by acquiring a division of Solventum that provides technologies and products used in the manufacturing of biologic drugs.
Adjusted EPS for the quarter came in at $1.41 against an anticipated $1.31 and revenue of $2.074 billion exceeded the expected $2.050 billion. Despite this, its adjusted free cash flow fell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results